Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. [electronic resource]
Producer: 20141108Description: E25-7 p. digitalISSN:- 1097-0347
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Agents -- metabolism
- Bevacizumab
- Drug Therapy, Combination
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
- Lapatinib
- Male
- Middle Aged
- Neoplasm, Residual
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- metabolism
- Salivary Ducts
- Salivary Gland Neoplasms -- drug therapy
- Trastuzumab
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.